The Trump administration is eroding national pandemic flu defenses as it guts health agencies, cuts research and health ...

President Donald Trump’s pick to be the next U.S. surgeon general has repeatedly said the nation’s medical, health and food ...

A novel immunoglobulin A nephropathy (IgAN) drug cut proteinuria in half, according to interim findings from the ongoing ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

A post-hoc analysis of the pivotal CANVAS trial shows those receiving higher dose canagliflozin are more likely to experience ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Its dividend: The stock recently yielded a whopping 7.3%. That's hard to beat and will generate around $730 for every $10,000 ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

Despite Pfizer management's cost-cutting and a large drug pipeline, revenue growth remains uncertain. Click here to read an ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...

Super-high-yield stocks often deliver heaps of passive income early on, but they aren't famous for rapid payout raises.